Art. -Nr.: HY-13273

Ostarine

(Synonyms: MK-2866; GTX-024; Enobosarm)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Ostarine (MK-2866) is a selective androgen receptor modulator (SARMs) that regulates cardiomyocyte function, improves bone healing, regulates uterine function, and influences muscle tissue metabolism.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 841205-47-8
Formel: C₁₉H₁₄F₃N₃O₃
Molecular Weight:389.33

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ostarine Chemical Structure

CAS. Nr.: 841205-47-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
CWR22R	IC₅₀	24.77 μM Compound: 44e; S-Enobosarm	Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human 22Rv1 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
DU-145	IC₅₀	44.55 μM Compound: 44e; S-Enobosarm	Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human DU145 cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
HEK293	IC₅₀	0.0038 μM Compound: 2	Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay	[PMID: 30525603]
LNCaP	IC₅₀	20.9 μM Compound: 44e; S-Enobosarm	Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human LNCAP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]
VCaP	IC₅₀	24.47 μM Compound: 44e; S-Enobosarm	Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay Antiproliferative activity against human VCaP cells after 96 hrs by propidium iodide staining based fluorescence 2D monolayer assay	[PMID: 27131065]

In Vitro

Ostarine (1000, 10000 nM) modulates the differentiation of H9C2 cardiomyocytes^[1].
Ostarine (1, 10, 100, 1000, 10000 nM) stimulates proliferation, cell viability, and differentiation of C2C12 and L6 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1].

Cell Line:

H9C2 cell
Concentration:

1000, 10000 nM
Incubation Time:

48 h
Result:

Increased production of myosin protein

Cell Proliferation Assay^[2].

Cell Line:

C2C12 and L6 cells
Concentration:

1, 10, 100, 1000, 10000 nM
Incubation Time:

48 h
Result:

Increased proliferation of C2C12 and L6 cells

Cell Viability Assay^[2].

Cell Line:

C2C12 and L6 cells
Concentration:

1, 10, 100, 1000, 10000 nM
Incubation Time:

48 h
Result:

Increased cell viability of C2C12 and L6 cells

In Vivo

Ostarine (0.4 mg/kg, 30 days, s.c.) stimulates profibrotic changes in male rat heart^[1].
Ostarine (0.4 mg/kg, 30 days, s.c.) stimulates muscle tissue proliferation and differentiation via the androgen receptor in rats sup>[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wistar rats^[1].
Dosage:

0.4 mg/kg, 30 days
Administration:

Subcutaneous injection (s.c.)
Result:

Increased the production of βMhc protein and the expression of βMhc, Tgfβ, Αsma, fibronectin, and BNP mRNA

Animal Model:

Male Wistar rats^[2].
Dosage:

0.4 mg/kg, 30 days
Administration:

Subcutaneous injection (s.c.)
Result:

Increased the expression of myogenin mRNA, myh mRNA and MyH protein content

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 841205-47-8
Appearance Solid
Molecular Weight 389.33
Formel C₁₉H₁₄F₃N₃O₃
Color White to off-white
SMILES

FC(F)(C1=C(C=CC(NC([C@@](C)(O)COC2=CC=C(C=C2)C#N)=O)=C1)C#N)F
Synonyms

MK-2866; GTX-024; Enobosarm
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All

Sort by:

Journal Impact Factor

Clin Chim Acta

Body fluid contamination in the context of an adverse analytical finding in doping: About a case involving ostarine. [Abstract]

2024 Apr 15:557:117871. PMID: 38467244
Drug Test Anal

Supramolecular Solvent Extraction for Doping Control Analysis of Prohibited Substances in Horse Urine. [Abstract]

2026 May;18(5):652-668. PMID: 41814125
Drug Test Anal

High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]

2021 Feb;13(2):283-298. PMID: 32852861
bioRxiv

2026 Jun 11.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (256.85 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5685 mL

12.8426 mL

25.6852 mL

5 mM

0.5137 mL

2.5685 mL

5.1370 mL

10 mM

0.2569 mL

1.2843 mL

2.5685 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.42 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Leciejewska N, et al. Sex-specific cytotoxicity of ostarine in cardiomyocytes. Mol Cell Endocrinol. 2023 Nov 1;577:112037. [Content Brief]

[2]. Leciejewska N, et al. Ostarine-Induced Myogenic Differentiation in C2C12, L6, and Rat Muscles. Int J Mol Sci. 2022 Apr 15;23(8):4404. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5685 mL	12.8426 mL	25.6852 mL	64.2129 mL
	5 mM	0.5137 mL	2.5685 mL	5.1370 mL	12.8426 mL
	10 mM	0.2569 mL	1.2843 mL	2.5685 mL	6.4213 mL
	15 mM	0.1712 mL	0.8562 mL	1.7123 mL	4.2809 mL
	20 mM	0.1284 mL	0.6421 mL	1.2843 mL	3.2106 mL
	25 mM	0.1027 mL	0.5137 mL	1.0274 mL	2.5685 mL
	30 mM	0.0856 mL	0.4281 mL	0.8562 mL	2.1404 mL
	40 mM	0.0642 mL	0.3211 mL	0.6421 mL	1.6053 mL
	50 mM	0.0514 mL	0.2569 mL	0.5137 mL	1.2843 mL
	60 mM	0.0428 mL	0.2140 mL	0.4281 mL	1.0702 mL
	80 mM	0.0321 mL	0.1605 mL	0.3211 mL	0.8027 mL
	100 mM	0.0257 mL	0.1284 mL	0.2569 mL	0.6421 mL

Keywords

Ostarine

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ostarine

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

Nuclear Receptor Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Ostarine

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ostarine

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

Nuclear Receptor Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Ostarine

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ostarine Related Classifications

Art. -Nr.: HY-13273